drugset / Trial / NCT00239720
PsA Treatment With hOKT3γ1 (Ala-Ala)
Phase 2
Terminated
4 enrolled
National Institute of Allergy and Infectious Diseases (NIAID)
Immune Tolerance Network (ITN) · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
hOKT3gamma1 (Ala-Ala) is a man-made antibody that is commonly used to prevent organ rejection. The purpose of this study is to determine whether hOKT3gamma1 (Ala-Ala) is safe and effective in psoriatic arthritis patients who are unable to control their arthritis with methotrexate or azathioprine.
Timeline
- Start
- 2006-03-16
- Primary completion
- 2006-12
- Completion
- 2008-06-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Teplizumab | Monoclonal antibody | 4 mg | Intravenous |